StockData
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. (VIR) stock

VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3036% below fair value
$8.39−0.48 (-5.41%)

Close on Nov 20, 2026Market cap $1.42BP/E –Yield –

Vir Biotechnology gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Vir Biotechnology's gross profit for the twelve months ending Jun 30, 2025 was $18.26M, down 76.6% year over year. For fiscal 2025 it was $68.53M, down 6.6% from the year before. The highest annual figure on record is $1.47B in fiscal 2022.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$68.53M-6.6%
FY2024Dec 31, 2024$73.36M-12.1%
FY2023Dec 31, 2023$83.42M-94.3%
FY2022Dec 31, 2022$1.47B+42.7%
FY2021Dec 31, 2021$1.03B+1248.1%
FY2020Dec 31, 2020$76.37M+843.9%
FY2019Dec 31, 2019$8.09M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$238.95M+10155.2%
Q2 FY2025Jun 30, 2025$1.20M-60.2%
Q1 FY2025Mar 31, 2025$3.03M-94.6%
Q4 FY2024Dec 31, 2024$11.69M-26.9%
Q3 FY2024Sep 30, 2024$2.33M-10.4%
Q2 FY2024Jun 30, 2024$3.02M-19.9%
Q1 FY2024Mar 31, 2024$56.32M-7.8%
Q4 FY2023Dec 31, 2023$15.99M-63.2%
Q3 FY2023Sep 30, 2023$2.60M-99.3%
Q2 FY2023Jun 30, 2023$3.78M–
Q1 FY2023Mar 31, 2023$61.05M-94.7%
Q4 FY2022Dec 31, 2022$43.41M-94.3%
Q3 FY2022Sep 30, 2022$352.30M+267.8%
Q2 FY2022Jun 30, 2022-$68.55M-139.0%
Q1 FY2022Mar 31, 2022$1.14B+57709.2%
Q4 FY2021Dec 31, 2021$755.87M+43491.1%
Q3 FY2021Sep 30, 2021$95.78M+4867.8%
Q2 FY2021Jun 30, 2021$175.92M+162.6%
Q1 FY2021Mar 31, 2021$1.98M–
Q4 FY2020Dec 31, 2020$1.73M–
Q3 FY2020Sep 30, 2020$1.93M–
Q2 FY2020Jun 30, 2020$66.99M–

More Vir Biotechnology figures

See a number that looks wrong?